Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
More articles/Ad
More articles/Ad
More articles
-
Risk appetite is back and more deals coming, though one bad IPO would damage confidence in the recovery
-
More companies are getting ratings to woo bond investors
-
Europe's biggest IPO of the year so far gains traction with investors
-
After the listings in February delivered, Galderma adds fuel to the European IPO recovery
-
Long delayed listing of Nestlé's former skincare division is finally underway
-
LivaNova and MicroStrategy ride US tech convertible wave as maturity wall pushes issuers to refinance